<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761395</url>
  </required_header>
  <id_info>
    <org_study_id>2814/10/14</org_study_id>
    <nct_id>NCT02761395</nct_id>
  </id_info>
  <brief_title>Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major</brief_title>
  <acronym>Al-hijamah</acronym>
  <official_title>Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Evaluate the therapeutic effects, health benefits, and immunological effect of&#xD;
           Al-hijamah in children with beta thalassemia major.&#xD;
&#xD;
        2. Evaluate the extent of clinical improvement, reductions in serum iron and ferritin,&#xD;
           antioxidant status, in those patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study will be carried on 60 children patients with β- thalassemia major attending&#xD;
      The Hematology Unit of Paediatric Departments at Tanta University Hospital. Participants will&#xD;
      divide into 3 groups:&#xD;
&#xD;
      Group 1: 20 patients receive Al-hijamah.&#xD;
&#xD;
      Group 2: 20 patients receive Al-hijamah plus iron chelation therapy.&#xD;
&#xD;
      Group 3: 20 patients receive iron chelation therapy only&#xD;
&#xD;
      Participants undergo:&#xD;
&#xD;
        1. Laboratory investigations:&#xD;
&#xD;
             -  CBC (complete blood count) of peripheral venous blood before Al-hijamah and daily&#xD;
                after it.&#xD;
&#xD;
             -  Differences between CBC from venous blood and cupped blood (bloody excretion&#xD;
                collected inside suction cups). Cupped blood is collected in heparin coated with&#xD;
                and added to suction cups put on the skin surface.&#xD;
&#xD;
                • Serum iron and ferritin before Al-hijamah and after it.&#xD;
&#xD;
                • Serum iron and ferritin in cupped blood vs venous blood.&#xD;
&#xD;
                • Serum lipid profile and glycosylated hemoglobin before Al-hijamah and after it.&#xD;
&#xD;
                  -  Total antioxidant capacity and some serum oxidants e.g. malondialdehyde before&#xD;
                     and after treatment&#xD;
&#xD;
                  -  Flow cytometric analysis of number of Natural killer cells, CD4 T helper cells&#xD;
                     and CD4/CD8 cells (optional) (cluster of differentiation). They were reported&#xD;
                     to improve markedly after Al-hijamah.&#xD;
&#xD;
                  -  Estimating serum LDH, pyruvate (antioxidant) and lactate (metabolite of&#xD;
                     pyruvate through LDH) in thalassemia patients before and after Al-hijamah&#xD;
&#xD;
        2. Assessment of heart function by Echocardiographic study (before and 3 month after&#xD;
           Al-hijamah):&#xD;
&#xD;
             -  lines of therapy:&#xD;
&#xD;
      Technical steps of Al-hijamah (Necessary equipments are ready and can do it for all patients&#xD;
      if possible):&#xD;
&#xD;
      Al-hijamah (Triple S technique under strict sterilization):&#xD;
&#xD;
        -  Strict sterilization of selected anatomical sites.&#xD;
&#xD;
        -  Suction using sterile plastic disposable sucking cups&#xD;
&#xD;
        -  Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth),&#xD;
           small (2 mm in length), multiple and evenly distributed skin incisions.&#xD;
&#xD;
        -  Suction using sterile plastic disposable sucking cups&#xD;
&#xD;
        -  Strict sterilization of selected anatomical sites.&#xD;
&#xD;
      Study endpoint:&#xD;
&#xD;
      This study will be terminated if safety of the patient were in dangers due to elements&#xD;
      related to the new therapeutic agent or if the treatment not proven efficacious.&#xD;
&#xD;
      5. Risks to participants are reasonable in relation to anticipated benefits. Many human&#xD;
      studies have proven safety of Al-hijamah.&#xD;
&#xD;
      6. Compensations of controls for transportation or work absence and of patients for any&#xD;
      injury, and if so, description of the compensation should be mentioned.&#xD;
&#xD;
      No, compensations.&#xD;
&#xD;
      7. The proposal include a clear statement that an informed consent will be obtained from all&#xD;
      participants in this research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD(cluster of differentiation)4 and CD8 count</measure>
    <time_frame>3month</time_frame>
    <description>count and percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum levels of cholesterol and triglyceride</measure>
    <time_frame>3month</time_frame>
    <description>level of cholesterol and triglyceride (mg per dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine amino transferase , aspartate amino transferase</measure>
    <time_frame>3month</time_frame>
    <description>measured as unit per litre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ferritin</measure>
    <time_frame>3 months</time_frame>
    <description>measured as ng per dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malodialdehyde ant total antioxidant capacity</measure>
    <time_frame>3 months</time_frame>
    <description>measuedas mmol per litre</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>AL-Hijama in Thalassmia Major</condition>
  <arm_group>
    <arm_group_label>Group 1: ALhijama</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients under went Al-hijamah procedure for iron chelation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: AL-hijama with deferasirox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients receive deferasirox and Al-hijamah.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3:deferasirox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients already receiving deferasirox</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Al-hijamah</intervention_name>
    <description>Strict sterilization of selected anatomical sites.&#xD;
Suction using sterile plastic disposable sucking cups&#xD;
Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions.</description>
    <arm_group_label>Group 1: ALhijama</arm_group_label>
    <arm_group_label>Group 2: AL-hijama with deferasirox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox</intervention_name>
    <description>20-40 mg/kg/day orally</description>
    <arm_group_label>Group 2: AL-hijama with deferasirox</arm_group_label>
    <arm_group_label>Group 3:deferasirox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children suffering from beta thalassemia major, with age range from 4-18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children with Congenital heart disease&#xD;
&#xD;
          -  Children with Rheumatic heart disease&#xD;
&#xD;
          -  Presence of heart failure&#xD;
&#xD;
          -  Children with Coronary arterial disease&#xD;
&#xD;
          -  Children with Cardiomyopathy&#xD;
&#xD;
          -  Children with hypotension&#xD;
&#xD;
          -  Children with inflammatory skin diseases e.g. acute burns&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed ELshanshory, prof</last_name>
    <role>Study Director</role>
    <affiliation>ethical committee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nahed Habas, MD</last_name>
    <phone>01010560350</phone>
    <phone_ext>002</phone_ext>
    <email>nahedhablas79@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammed El shanshoryR, Prof.</last_name>
    <phone>01005680834</phone>
    <phone_ext>002</phone_ext>
    <email>elshanshory@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine- Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <zip>0000</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine- Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <zip>0000</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed R El-Shanshory, MD</last_name>
      <phone>+201005680834</phone>
      <email>elshanshory@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nahed M Hablas, MD</last_name>
      <phone>+201010560350</phone>
      <email>nahedhablas79@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamed M El-Shanshory, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nahed AR Hablas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salah M El Sayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>January 30, 2016</study_first_submitted>
  <study_first_submitted_qc>May 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

